Xinhua Pharmaceutical: Subsidiary obtains registration certificate for Saxagliptin Metformin sustained-release tablets.

Xinhua Pharmaceutical announced that its wholly-owned subsidiary Xinda Pharmaceutical has received the approved and issued "Drug Registration Certificate" for the Saxagliptin and Metformin Hydrochloride Extended-release Tablets from the National Medical Products Administration. This product, in combination with diet and exercise therapy, is suitable for adults with type 2 diabetes and is classified as a category B variety in the medical insurance catalog. The sales of this drug in public medical institutions in China are expected to reach approximately 419 million yuan in 2024. The approval is beneficial for enriching the company's series of antidiabetic drugs and enhancing overall competitiveness, but drug sales are subject to various factors and uncertainties.